Nitisinone Dipharma (Nitisinone)

Nitisinone blocks the enzyme p‑hydroxyphenylpyruvate dioxygenase (HPPD) in the tyrosine degradation pathway. By inhibiting this step, the drug prevents formation of downstream toxic metabolites such as maleylacetoacetate and fumarylacetoacetate, thereby protecting liver and kidney function.

The specific dose of Nitisinone Dipharma is determined by the prescribing physician based on the patient’s age, weight, disease severity, and laboratory monitoring. Healthcare professionals tailor the regimen to achieve optimal metabolic control while minimizing adverse effects.

Safety data for nitisinone in pregnancy and lactation are limited, and the pregnancy category is unknown. It should be used only if the potential benefit justifies the possible risk to the fetus, and breastfeeding decisions should be made in consultation with a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Nitisinone is the primary disease‑modifying therapy for hereditary tyrosinemia type I, directly targeting the metabolic defect. Alternative approaches, such as liver transplantation, address end‑stage disease but do not correct the underlying enzyme deficiency. Nitisinone therefore offers a less invasive, pharmacologic option that can delay or avoid transplantation.

Nitisinone Dipharma should be stored at temperatures below 25 °C, in a dry place away from direct sunlight. Keep the product in its original packaging to protect it from moisture and handle it according to the label instructions to maintain stability.

The medication is supplied as an oral formulation and should be taken by mouth with water, usually once daily or as directed by the prescriber. Doses are often adjusted based on regular monitoring of blood and urine metabolites, as well as liver function tests.

Serious risks include severe liver injury, hypoglycemia, and peripheral neuropathy. Patients should be monitored closely for signs of hepatic dysfunction, unexplained low blood sugar, or neurological symptoms, and any concerning findings should prompt immediate medical evaluation.

Individuals with known hypersensitivity to nitisinone or any of its excipients should avoid the product. Caution is also advised for patients with pre‑existing severe liver disease, uncontrolled renal impairment, or those taking concomitant medications that pose a high risk of hepatotoxicity.